Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Video Expert Opinion
Colleague Insights
Living Resources
Conferences
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Access expired on Thursday, July 16, 2020

This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.

Already Have An Account? Log in Now

Register Now
featured
Published in Bladder Cancer and
1 other channel

Expert Opinion / Interview · August 28, 2020

ASCO: Outcomes of Patients With Metastatic Urothelial Carcinoma Following Discontinuation of Enfortumab-Vedotin

Matthew Mossanen MD, MPH
Guru Sonpavde MD
Interview with
Guru P. Sonpavde MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Guru Sonpavde MD

Further Reading

Related Videos